Literature DB >> 15736144

Anal intraepithelial neoplasia.

F Abbasakoor1, P B Boulos.   

Abstract

BACKGROUND: Anal intraepithelial neoplasia (AIN) is believed to be a precursor of anal squamous cell cancer and its incidence is rising in high-risk groups, particularly those infected with the human immunodeficiency virus (HIV). The natural history of AIN is unclear and management strategies are lacking.
METHODS: This review is based on a literature search (Medline and PubMed) with manual cross-referencing of all articles related to AIN. RESULTS AND
CONCLUSIONS: The aetiology of AIN is intricately linked with human papilloma viruses. The pathological processes involved in the progression of AIN are becoming clearer but the natural history, particularly the rate of progression to invasive cancer, remains unknown. There is no standard management for AIN and this is mainly due to difficulties in both diagnosis and treatment. A variety of treatment options have been tried with varying success. Surgery is associated with significant recurrence, particularly in HIV-positive patients. Non surgical approaches with imiquimod, photodynamic therapy and vaccination are appealing, and further work is required. Long-term follow-up of these patients is essential until the natural history of AIN becomes clearer. Copyright (c) 2005 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15736144     DOI: 10.1002/bjs.4967

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  21 in total

Review 1.  Anal Intraepithelial Neoplasia and Squamous Cell Cancer of the Anus.

Authors:  Rebecca E Hoedema
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 2.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.

Authors:  Antona J Wagstaff; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Description of a pilot anal pap smear screening program among individuals attending a Veteran's Affairs HIV clinic.

Authors:  Isabella Rosa-Cunha; Vincent A Degennaro; Rene Hartmann; Clara Milikowski; Andres Irizarry; Brenda Heitman; Orlando Gómez-Marín; Gordon M Dickinson
Journal:  AIDS Patient Care STDS       Date:  2011-03-02       Impact factor: 5.078

Review 4.  Screening, Surveillance, and Treatment of Anal Intraepithelial Neoplasia.

Authors:  Kevin C Long; Raman Menon; Amir Bastawrous; Richard Billingham
Journal:  Clin Colon Rectal Surg       Date:  2016-03

5.  Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV-positive and HIV-negative men who have sex with men.

Authors:  Jasmeet Chadha Singh; Victoria Kuohung; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

Review 6.  Human immunodeficiency disease: how should it affect surgical decision making?

Authors:  T E Madiba; D J J Muckart; S R Thomson
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

7.  Anal dysplasia screening: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2007-06-01

8.  Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms.

Authors:  Anette Duensing; Anna Chin; Linan Wang; Shih-Fan Kuan; Stefan Duensing
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

Review 9.  Diagnosis and management of anal cancer.

Authors:  Pascal Gervaz; Nicolas Buchs; Philippe Morel
Journal:  Curr Gastroenterol Rep       Date:  2008-10

10.  Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.

Authors:  Ruey-Shyang Soong; Liwen Song; Janson Trieu; Jayne Knoff; Liangmei He; Ya-Chea Tsai; Warner Huh; Yung-Nien Chang; Wen-Fang Cheng; Richard B S Roden; T-C Wu; Cornelia L Trimble; Chien-Fu Hung
Journal:  Clin Cancer Res       Date:  2014-06-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.